Several USP5 inhibitors have been proposed for human cancers, such as PYR-41, formononetin [44], and WP1130 or one of its optimized analogues EOAI3402143 (G9) [45,46], but these compounds do not exclusively target USP5. Here, USP5 is linked to cancer.